FGFR3 and skeletal dysplasia: Representatives from Spain, Belgium and the UK stated that a targeted skeletal dysplasia panel is used, which limits incidental findings from a full exome analysis, while those from France and Portugal preferred targeted variant analysis, with the option to subsequently carry out a skeletal dysplasia panel if the recurrent achondroplasia FGFR3 variant is not identified.